Q3'25 Financial Performance - Life360's Q3'25 revenue reached $124.5 million, a 34% year-over-year increase[19, 125] - Adjusted EBITDA for Q3'25 was $24.5 million, representing a 20% margin[19, 125] - Global Paying Circles grew to approximately 2.7 million, a 23% year-over-year increase[19, 125] - Annualized Monthly Revenue (AMR) increased by 33% to $446.7 million[126] User Engagement and Growth - Global Monthly Active Users (MAU) reached approximately 91.6 million, a 19% year-over-year increase[19, 125] - International MAU experienced a 24% year-over-year growth[125] - Life360 is ranked as the 7 top social networking app by DAU in the U S[19] Revenue Breakdown - Subscription revenue was $96.3 million, a 34% year-over-year increase[126] - Hardware revenue was $11.3 million, a 4% year-over-year decrease[126] - Other revenue, including data and partnership agreements, was $16.9 million, an 82% year-over-year increase[126] FY'25 Outlook - Life360 expects consolidated revenue of $474 million to $485 million for FY'25[169] - The company anticipates positive Adjusted EBITDA of $84 million to $88 million for FY'25[168]

03-2025 INFESTOR UPDATE Sir Peter Beck, CEO Adam Spice, CFO November 10, 2025 ROCKETLAB Forward Looking Statements This presentation may contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our expec ...

SAFE HARBOR This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as "guidance," "believe," "expect," "estimate," "project," "plan," "will," or words or phrases with similar meaning. Forward-looking statements s ...

Exhibit 99.2 Q3 2025 Earnings Supplement November 2025 Disclaimer 1 Repay Holdings Corporation ("REPAY" or the "Company") is required to file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission ("SEC") Such filings, which you may obtain for free at the SEC's website at http://www.sec.gov, discuss some of the important risk factors that may affect REPAY's business, results of operations and financial condition. Forward-Looking Statements T ...

Financial Performance - The RealReal achieved a record quarterly GMV of $520 million, a 20% year-over-year increase[20, 24] - Revenue reached $174 million, up 17% year-over-year, with Consignment Revenue increasing by 15% and Direct Revenue by 47%[29] - Adjusted EBITDA was $9.3 million, representing 5.4% of Total Revenue, a 380 basis points year-over-year increase[20, 31] - The company generated $14 million in Free Cash Flow[20] Operational Efficiency and Scalability - Athena, the company's AI-enabled product intake process, scaled to approximately 27% of all units and is on track for 30-40% by year-end[20] - Consignment Gross Margin increased by 70 basis points year-over-year to 89.3%[20] - Operating Expenses improved by 620 basis points year-over-year as a percentage of revenue due to operating efficiencies, AI and automation, and fixed cost leverage[20, 34] Customer Engagement - Active Buyers reached an all-time high of 1.024 million, a 7% increase on a trailing 12-month basis[20, 26] - Supply value per existing Luxury Manager increased by 12% year-over-year, driven by a new compensation plan and AI investments[20] - Over 80% of GMV comes from repeat customers[44] Outlook - The company raised its Full-Year 2025 Guidance[20] - The FY25 Adjusted EBITDA outlook reflects approximately 400 basis points margin expansion versus 2024 at the guidance midpoint[20] - Full year GMV is projected to be between $2.099 billion and $2.109 billion[36] - Full year Revenue is projected to be between $687 million and $690 million[36] - Full year Adjusted EBITDA is projected to be between $37.7 million and $38.7 million[36]

Financial Highlights - FibroGen completed the sale of FibroGen China to AstraZeneca for approximately $220 million[3, 50] - The sale included an enterprise value of $85 million and approximately $135 million of FibroGen net cash held in China[50] - The company successfully repaid its term loan to Morgan Stanley Tactical Value[3, 50] - FibroGen extended its cash runway into 2028[3, 50] FG-3246 and FG-3180 Program (Prostate Cancer) - Phase 2 monotherapy trial of FG-3246 and FG-3180 in mCRPC (post-ARPI / pre-chemo setting) has been initiated, with interim results expected in 2H 2026[3, 17, 18] - In a Phase 1 monotherapy study, FG-3246 showed a median rPFS of 8.7 months and a PSA decline of >50% in approximately 36% of patients[15] - In a Phase 1b combination study with enzalutamide, FG-3246 showed a preliminary estimate of median rPFS of 10.2 months and PSA declines in 71% of evaluable patients[15] - Topline results from an investigator-sponsored trial (IST) of FG-3246 in combination with enzalutamide in mCRPC are expected in 1Q 2026[3, 15] Roxadustat (Anemia of LR-MDS) - Roxadustat is being developed as a late-stage development opportunity for anemia due to LR-MDS and high red blood cell transfusion burden[3, 36] - In a post-hoc analysis of the MATTERHORN Phase 3 trial, roxadustat showed promising transfusion independence (TI) benefits compared to placebo in patients with high transfusion burden, with 36% achieving 8-week RBC-TI within 28 weeks compared to 7% for placebo[37, 38] - Phase 3 protocol submission is anticipated in 4Q 2025 for roxadustat in anemia of LR-MDS, with potential Phase 3 initiation in 2026[3, 45]

Theravance Biopharma Third Quarter 2025 Financial Results and Business Update November 10, 2025 THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third-party trademarks used herein are the property of their respective owners. © 2025 Theravance Biopharma. All rights reserved. Forward Looking Statements Examples of such statements include statement ...

Nasdaq: HIT 22,40,80 30,109,175 210,20,125 This Presentation has been prepared by the Company solely for informational purposes. The information included herein in this presentation has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of it' s affiliates, advisers or representatives or the underwriters as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opini ...

Q3 2025 Financial Performance - Non-GAAP Revenue increased by 21% to $492 million[5, 19] - Adjusted EBITDA declined by 17% to $23.6 million[5, 19] - Non-GAAP EPS decreased by 54% to $0.06[5, 20] - Consumer Services revenue was down 10% to $88.3 million[21] - B2B Services revenue increased by 32% to $364.2 million[21] - Money Movement revenue decreased by 6% to $29.8 million[21] Key Metrics - Active accounts increased by 1%[6, 28] - B2B Services active accounts increased 13% offsetting a 9% decline in Consumer Services active accounts[31] - Gross Dollar Volume (GDV) increased by 18%[29] 2025 Guidance - Projected Non-GAAP Revenue is expected to be between $2 billion and $2.1 billion, representing a 20% growth at the mid-point[61, 62] - Projected Adjusted EBITDA is expected to be between $165 million and $175 million[61] - Projected Non-GAAP EPS is expected to be between $1.31 and $1.44[61]

Financial Performance - Revenue for Q3 2025 reached $1498 million, a 204% increase year-over-year[15] - Adjusted EBITDA for Q3 2025 was $196 million, up 161% year-over-year[15] - The adjusted EBITDA margin was 131% in Q3 2025, a decrease of 40 bps year-over-year[15] - Free Cash Flow for Q3 2025 was $(4) million[32] - The company is raising its 2025 revenue guidance to $5970 - $6030 million, representing a 14% to 15% year-over-year increase[21] - The company is raising its 2025 Free Cash Flow guidance to $170 - $190 million[21] Segment Performance - Engine Services revenue grew by 213% year-over-year in Q3 2025[34] - Component Repair Services revenue grew by 139% year-over-year in Q3 2025[39] - Component Repair Services achieved an adjusted EBITDA margin of 307% in Q3 2025, an increase of 430 bps year-over-year[39] Balance Sheet - The Net Debt to Adjusted EBITDA leverage ratio improved to 29x[50]